Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Declines By 39.6%

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 50,400 shares, a decrease of 39.6% from the December 15th total of 83,400 shares. Based on an average daily volume of 48,500 shares, the short-interest ratio is presently 1.0 days. Currently, 1.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Price Performance

Shares of BCDA opened at $2.25 on Tuesday. The firm has a market capitalization of $10.31 million, a PE ratio of -0.54 and a beta of 1.26. BioCardia has a fifty-two week low of $1.63 and a fifty-two week high of $9.90. The company’s 50-day moving average is $2.20 and its 200-day moving average is $2.59.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.